Drug Trial Radar · NCT04304040
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
43
Actual
Start
Jul 28, 2020
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma
Conditions
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
Interventions
OrelabrutinibDrug
BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
Recombinant humanized monoclonal antibody MIL62 injectionDrug
Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)(Dose escalation phase)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Maximum tolerated dose (MTD) (Dose escalation phase)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Recommended dose for phase 2 trials of two-drug combinations (RP2D) (Dose escalation phase)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- objective remission rate(ORR) (Dose expansion phase)Time frame: At the end of Cycle 30 (each cycle is 28 days)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Beijing Hospital
Beijing, Beijing Municipality, China
Beijing Shijitan hospital, capital medical university
Beijing, Beijing Municipality, China
Cancer hospital, Chinese academy of medical sciences
Beijing, Beijing Municipality, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Henan Tumor Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.